Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-2084.

Published: 16th October 2012

Authors: Van Hagen P, Hulsof MCCM, van Lanschot JJB, Steyerberg EW, Henegouwen MIBV, Wijnhoven BPL et al. et al.

Conclusion

The neoadjuvant chemoradiotherapy lasted five weeks in this study that included 368 patients. Treated patients had a higher rate of complete resection with no tumour within 1mm of resection margins: 92 versus 69 per cent (P<0.001). Median overall survival rates were 49 and 24 months, respectively, P=0.003.

Pubmed Link

Your comments

0 Comments